Gonorrhea treatment failures with oral and injectable expanded spectrum cephalosporin monotherapy vs dual therapy at 4 canadian sexually transmitted infection clinics, 2010-2013

Sexually Transmitted Diseases

Volumn 42, Issue 6, 2015, Pages 331-336

  Singh, Ameeta E ^a   Gratrix, Jennifer ^a   Martin, Irene ^a   Friedman, Dara S ^a   Hoang, Linda ^a   Lester, Richard ^a   Metz, Gila ^a   Ogilvie, Gina ^a   Read, Ron ^a   Wong, Tom ^a  

^a ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; DOXYCYCLINE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANADA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GONORRHEA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TREATMENT OUTCOME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CANADA; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84929883999     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000280     Document Type: Article

References (34)

1. Ison CA, Deal C, Unemo M. Current and future treatment options for gonorrhoea. Sex Transm Infect 2013; 89(suppl 4):iv52-iv56.
2. Public Health Agency of Canada. Notifiable Diseases On Line. Available at: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/charts.php? c=yl. Accessed July 19, 2014.
3. Public Health Agency of Canada, 2006. Canadian Guidelines on Sexually Transmitted Infections-Gonorrhea chapter (no longer available online).
4. Centers forDisease Control and Prevention (CDC). Sexually Transmitted Disease Surveillance Supplement 2007, Gonococcal Isolate Surveillance Project Annual Report 2007 Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at: http://www.cdc. gov/std/gisp2007/gispsurvsupp2007short.pdf.Accessed February 11, 2015.
5. Public Health Agency of Canada. National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Annual Summary 2013. 2014.
6. Public Health Agency of Canada, 2011. Important Notice-Public Health Information Update on the Treatment of Gonococcal Infection. Available at: http://www.phac-aspc.gc.ca/std-mts/sti-its/alert/2011/ alert-gono-eng.php. Accessed June 25, 2014.
7. AllenVG,Mitterni L, Seah VG, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163-170.
8. Gratrix J, Bergman J, Egan C, et al. Retrospective reviewof pharyngeal gonorrhea treatment failures in Alberta, Canada. Sex Transm Dis 2013; 40:877-879.
9. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: Time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65:2141-2148.
10. Pereira R, Cole MJ, Ison CA. Combination therapy for gonorrhoea: In vitro synergy testing. J Antimicrob Chemother 2013; 68:640-643.
11. Furuya R, Koga Y, Irie S, et al. In vitro activities of antimicrobial combinations against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2013; 19:1218-1220.
12. Barbee AL, Soge OO, Holmes KK, Golden MR. In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae. J Antimicrob Chemother 2014; 69:1572-1578.
13. Wind CM, de VriesHJ, vanDam AP. Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution. Int J Antimicrob Agents 2015; 45: 305-308.
14. Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013; 56: 1539-1545.
15. Sathia L, Ellis B, Phillip S, et al. Pharyngeal gonorrhoea-Is dual therapy the way forward? Int J STD AIDS 2007; 18:647-648.
16. World Health Organization. Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae, 2012. Available at: http://whqlibdoc.who.int/publications /2012/9789241503501-eng.pdf?ua=1. Accessed July 11, 2014.
17. Martin IM, Ison CA, Aanensen DM, et al. Rapid sequence based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189:1497-1505.
18. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9:35-39.
19. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15(47): pii: 19721.
20. Manavi K, Young H, McMillan A. The outcome of oropharyngeal gonorrhoea treatment with different regimens. Int J STD AIDS 2005; 16:68-70.
21. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2010:Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590-594.
22. Bignell C, UnemoM. European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24:85-92.
23. Ison CA, Town K, Obi C, et al. GRASP collaborative group. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 2013; 13:762-768.
24. Kirkcaldy RD, Kidd S,WeinstockHS, et al. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: The Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 2013; 89(suppl 4):iv5-iv10.
25. Bignell CJ. BASHH guidelines for gonorrhoea. Sex Transm Infect 2004; 80:330-331.
26. Singh AE, Gratrix J, Read R, et al. Neisseria gonorrhoeae multiantigen sequence typing (NG-MAST) is beneficial in further characterizing gonococcal populations in Alberta, Canada. Sex Transm Dis 2013; 40:744-750.
27. Hottes TS, Lester RT, Hoang LM, et al. Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis 2013; 40:46-51.
28. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58:683-687.
29. Golparian D, Hellmark B, Fredlund H, et al. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrumcephalosporins in Sweden. Sex Transm Infect 2010; 86:454-460.
30. Chisholm SA, Alexander S, Desouza-Thomas L, et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother 2011; 66:2509-2512.
31. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273-1280.
32. GoldenMR, Barbee LA, Kerani R, et al. Potential deleterious effects of promoting the use of ceftriaxone in the treatment of Neisseria gonorrhoeae. Sex Transm Dis 2014; 41:619-625.
33. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676-685.
34. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N. gonorrhoeae. Sex Transm Infect 2013; 89 (suppl 4):iv47-iv51.